|
⚲
|
| Keyboard |
| Johnson & Johnson
✚
|
|
|---|---|
| CIK # | 0000200406 |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Protagonist Therapeutics Inc | 0.3 | ||
| Nanobiotix Sa | 0.2 | ||
| MeiraGTx Holdings PLC | 0.1 | ||
| Rapport Therapeutics Inc | 0.1 | ||
| CVRX Inc | 0.0 | ||
| Contineum Therapeutics Inc | 0.0 | ||
| Legend Biotech Corp | 0.0 | ||
| Xencor Inc | 0.0 | ||
| Procept Biorobotics Corp | 0.0 | ||
| Fate Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 10-K | [0000200406] | |
| 10-Q | [0000200406] | |
| 13F-HR | [0000200406] | |
| 13F-NT | [0000200406] | |
| 3 | [0000200406] | |
| 4 | [0000200406] | |
| 5 | [0000200406] | |
| 8-K | [0000200406] | |
| SC 13G | [0000200406] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Johnson & Johnson | |
| Wengel Kathryn E | |
| Woods Eugene A | |
| Hewson Marillyn A | |
| Pinto Daniel E | |
| Reed John C | |
| McClellan Mark B | |
| Morikis John G | |
| Weinberger Mark A | |
| West Nadja | |
| View All | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Johnson & Johnson JNJ
Deferred Share Units · derivative
|
2026-03-10 | Grant | 206.49 | $242.14 | 49,999 |
|
Johnson & Johnson JNJ
Deferred Share Units · derivative
|
2026-03-10 | Grant | 129.06 | $242.14 | 31,251 |
|
Johnson & Johnson JNJ
Deferred Share Units · derivative
|
2026-03-10 | Grant | 154.87 | $242.14 | 37,500 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-27 | Option exercise | 4,075 | $115.67 | 471,355 |
|
Johnson & Johnson JNJ
Employee Stock Options (Right to Buy) · derivative
|
2026-02-27 | Option exercise | 4,075 | $0.00 | |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-27 | Sell | 4,075 | $247.87 | 1,010,070 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-20 | Sell | 1,322 | $245.66 | 324,763 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-18 | Option exercise | 13,625 | $115.67 | 1,576,004 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-18 | Option exercise | 8,998 | $129.51 | 1,165,331 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-18 | Sell | 13,625 | $244.20 | 3,327,225 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-18 | Sell | 8,998 | $244.53 | 2,200,281 |
|
Johnson & Johnson JNJ
Employee Stock Options (Right to Buy) · derivative
|
2026-02-18 | Option exercise | 8,998 | $0.00 | |
|
Johnson & Johnson JNJ
Employee Stock Options (Right to Buy) · derivative
|
2026-02-18 | Option exercise | 13,625 | $0.00 | |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Option exercise | 12,066 | $129.51 | 1,562,668 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Sell | 19,241 | $242.99 | 4,675,371 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Sell | 12,066 | $242.87 | 2,930,469 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Sell | 29,927 | $243.00 | 7,272,261 |
|
Johnson & Johnson JNJ
Employee Stock Options (Right to Buy) · derivative
|
2026-02-17 | Option exercise | 33,386 | $0.00 | |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Sell | 6,197 | $243.39 | 1,508,288 |
|
Johnson & Johnson JNJ
Common Stock
|
2026-02-17 | Sell | 24,961 | $242.68 | 6,057,535 |
| showing 20 of 200 most recent transactions | |||||